Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice

British Journal of Pharmacology

Volumn 156, Issue 1, 2009, Pages 173-180

  Yano, K ^a   Koda, K ^a   Ago, Y ^a   Kobayashi, H ^a   Kawasaki, T ^a   Takuma, K ^a   Matsuda, T ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

ACh release; AChE inhibitor; Apomorphine; Donepezil; Dopamine release; Galantamine; Muscarinic ACh receptor (mAChR); Prepulse inhibition

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETYLCHOLINE; APOMORPHINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; GALANTAMINE; MECAMYLAMINE; MUSCARINIC RECEPTOR; OXOTREMORINE; TELENZEPINE; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; INDAN DERIVATIVE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PIPERIDINE DERIVATIVE; PIRENZEPINE; SEROTONIN;

ACETYLCHOLINE BRAIN LEVEL; ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DATA ANALYSIS; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; ENZYME INHIBITION; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; STARTLE REFLEX; ANIMAL; ANIMAL BEHAVIOR; AUDITORY STIMULATION; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; INHIBITION (PSYCHOLOGY); METABOLISM; OUTBRED STRAIN; PHYSIOLOGY;

ACETYLCHOLINE; ACOUSTIC STIMULATION; ANIMALS; ANIMALS, OUTBRED STRAINS; APOMORPHINE; BEHAVIOR, ANIMAL; BENZAZEPINES; CHOLINESTERASE INHIBITORS; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GALANTAMINE; INDANS; INHIBITION (PSYCHOLOGY); MALE; MECAMYLAMINE; MICE; MICRODIALYSIS; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; NICOTINIC ANTAGONISTS; OXOTREMORINE; PIPERIDINES; PIRENZEPINE; PREFRONTAL CORTEX; RECEPTORS, MUSCARINIC; SEROTONIN; STARTLE REACTION;

EID: 65549138841     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00037.x     Document Type: Article

References (58)

1. 1 receptor agonist A-77636 increases cortical and hippocampal acetylcholine release in the rat. Eur J Pharmacol 260 : 85 87.
2. Acri JB, Morse DE, Popke EJ, Grunberg NE (1994). Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacology (Berl) 114 : 369 374.
3. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K et al. (1998). Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24 : 189 202. (Pubitemid 28404980)
4. 1A receptor-mediated dopamine release in vivo in the frontal cortex of mice. J Neurochem 83 : 353 359.
5. 1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology 45 : 1050 1056.
6. 1A receptor agonist, osemozotan, of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology 51 : 914 922.
7. Ago Y, Sato M, Nakamura S, Baba A, Matsuda T (2006b). Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex. J Pharmacol Sci 102 : 419 422.
8. Ago Y, Nakamura S, Kajita N, Uda M, Hashimoto H, Baba A et al. (2007). Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice. Synapse 61 : 757 763. (Pubitemid 47122748)
9. + channels by galantamine can also contribute to the potentiation of catecholamine secretion from chromaffin cells. Eur J Pharmacol 548 : 45 52.
10. Bitsios P, Giakoumaki SG, Theou K, Frangou S (2006). Increased prepulse inhibition of the acoustic startle response is associated with better strategy formation and execution times in healthy males. Neuropsychologia 44 : 2494 2499.
11. Braff DL, Swerdlow NR, Geyer MA (1999). Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry 156 : 596 602.
12. Bubser M, Koch M (1994). Prepulse inhibition of the acoustic startle response of rats is reduced by 6 hydroxydopamine lesions of the medial prefrontal cortex. Psychopharmacology (Berl) 113 : 487 492.
13. Bymaster FP, Heath I, Hendrix JC, Shannon HE (1993). Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267 : 16 24.
14. Castañé A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O (2002). Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43 : 857 867.
15. 1B receptors. J Pharmacol Exp Ther 277 : 823 830.
16. 2+ signals and neurotransmitter release. Mol Pharmacol 64 : 1217 1226.
17. Damaj MI, Welch SP, Martin BR (1995). In vivo pharmacological effects of dihydro-β-erythroidine, a nicotinic antagonists, in mice. Psychopharmacology (Berl) 117 : 67 73.
18. 1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. Int J Neuropsychopharmacol 10 : 383 399.
19. Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA (1987). Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther 242 : 257 262.
20. Eltze M, Gonne S, Riedel R, Schlotke B, Schudt C, Simon WA (1985). Pharmacological evidence for selective inhibition of gastric acid secretion by telenzepine, a new antimuscarinic drug. Eur J Pharmacol 112 : 211 224.
21. Franklin KBJ, Paxinos G (1997). The Mouse Brain in Stereotaxic Coordinates. Academic Press, Inc San Diego, CA.
22. Freeman GB, Sherman KA, Gibson GE (1987). Locomotor activity as a predictor of times and dosages for studies of nicotine's neurochemical actions. Pharmacol Biochem Behav 26 : 305 312.
23. Friedman JI (2004). Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 174 : 45 53.
24. Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, Sachak S (2005). Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 1033 : 186 193.
25. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NE (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 : 117 154.
26. Giacobini E, Zhu XD, Williams E, Scherman KA (1996). The effect of the selective reversible acetylcholinesterase inhibitor, E2020, on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35 : 205 211.
27. Graham FK (1975). The more or less startling effects of weak prestimulation. Psychophysiology 12 : 238 248.
28. Hatip-Al-Khatib I, Takashi A, Egashira N, Iwasaki K, Fujiwara M (2004). Comparison of the effect of TAK-147 (zanapezil) and E-2020 (donepezil) on extracellular acetylcholine level and blood flow in the ventral hippocampus of freely moving rats. Brain Res 1012 : 169 176.
29. Hersi AI, Richard JW, Gaudreau P, Quirion R (1995). Local modulation of hippocampal acetylcholine release by dopamine D1 receptors: a combined receptor autoradiography and in vivo dialysis study. J Neurosci 15 : 7150 7157.
30. Hohnadel E, Bouchard K, Terry AV Jr. (2007). Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology 52 : 542 551.
31. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26 : 325 339.
32. 2 receptors facilitates in vivo acetylcholine release in the hippocampus. Brain Res 618 : 341 345. (Pubitemid 23207979)
33. Isomae K, Ishikawa M, Ohta M, Ogawa Y, Hasegawa H, Kohda T et al. (2002). Effects of T-82, a new quinoline derivative, on cholinesterase activity and extracellular acetylcholine concentration in rat brain. Jpn J Pharmacol 88 : 206 212.
34. Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE (2005). Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 312 : 1055 1063.
35. de Jong IE, van den Buuse M (2006). SCH 23390 in the prefrontal cortex enhances the effect of apomorphine on prepulse inhibition of rats. Neuropharmacology 51 : 438 446.
36. Kawashima K, Sato A, Yoshizawa M, Fujii T, Fujimoto K, Suzuki T (1994). Effects of the centrally acting cholinesterase inhibitors, tetrahydroaminoacridine and E2020, on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 350 : 523 528.
37. Koda K, Ago Y, Kawasaki T, Hashimoto H, Baba A, Matsuda T (2008). Galantamine and donepezil differently affect i/ation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl) 196 : 293 301.
38. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y (1999). Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 380 : 101 107. (Pubitemid 29469519)
39. Kumari V, Checkley SA, Gray JA (1996). Effects of cigarette smoking on prepulse inhibition of the acoustic startle reflex in healthy male smokers. Psychopharmacology (Berl) 128 : 54 60.
40. Kumari V, Cotter PA, Checkley SA, Gray JA (1997). Effects of acute subcutaneous nicotine on prepulse inhibition of the acoustic startle reflex in healthy male non-smokers. Psychopharmacology (Berl) 132 : 389 395.
41. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX et al. (2001). Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49 : 279 288.
42. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS et al. (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 160 : 118 127.
43. Reid RT, Lloyd GK, Rao TS (1999). Pharmacological characterization of nicotine-induced acetylcholine release in the rat hippocampus in vivo: evidence for a permissive dopamine synapse. Br J Pharmacol 127 : 1486 1494.
44. Rogers SL, Yamanishi Y, Yamatsu K (1991). E2020: the pharmacology of a piperidine cholinesterase inhibitor. In : Becker R, Giacobini E (eds). Cholinergic Basis for Alzheimer Therapy. Birkhäuser Boston : Cambridge, pp. 314 320.
45. 1A receptor agonist, MKC-242, reverse i/ation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl) 170 : 73 79.
46. Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C et al. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305 : 1024 1036.
47. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A et al. (2002). The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61 : 1222 1234.
48. 1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. Eur J Pharmacol 559 : 155 160.
49. Schilström B, Ivanov VB, Wiker C, Svensson TH (2007). Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 32 : 43 53.
50. Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 : 583 594.
51. 1A receptor agonist, facilitates cortical acetylcholine release by a mechanism different from that of 8-OH-DPAT in awake rats. Neuropharmacology 36 : 1733 1739.
52. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB et al. (2001). The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299 : 782 792.
53. 7 receptors. Br J Pharmacol 142 : 843 850.
54. Sweeney JE, Bachman ES, Coyle JT (1990). Effects of different doses of galantamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology (Berl) 102 : 191 200.
55. Swerdlow NR, Lipska BK, Weinberger DR, Braff DL, Jaskiw GE, Geyer MA (1995). Increased sensitivity to the sensorimotor gatingdisruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology (Berl) 122 : 27 34.
56. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL (2006). Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63 : 1325 1335.
57. Tani Y, Saito K, Imoto M, Ohno T (1998). Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain - an in vivo microdialysis study. Eur J Pharmacol 351 : 181 188.
58. Woodruff-Pak DS, Lander C, Geerts H (2002). Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 8 : 405 426.